DDInter90 DDInter1082
Amprenavir is a protease inhibitor used to treat HIV infection.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Amprenavir {u} (Compound) resembles {v} (Compound) Darunavir
Amprenavir {u} (Compound) resembles {v} (Compound) Fosamprenavir
Amprenavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Amprenavir {u} (Compound) binds {v} (Gene) ABCB1
Amprenavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Amprenavir {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Amprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zafirlukast
Amprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Amprenavir (Compound) resembles Darunavir (Compound)
Amprenavir (Compound) resembles Fosamprenavir (Compound)
Amprenavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Amprenavir (Compound) binds ABCB1 (Gene)
Amprenavir (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Amprenavir (Compound) causes Musculoskeletal discomfort (Side Effect)
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone